This is an old revision of the document!


Rapamycin effects on aging-associated pathologies

Objectives

Rapamycin is an inhibitor of the mTOR pathway, which has been used in preventing rejection of solid organ allografts. In this multi-PI study on an older age healthy human cohort, we assess the usability and efficacy of Rapamycin in improving physical performance, cardiac and vascular health, and immune outcomes. This approach is motivated by the promising results that were observed in prior studies on mice models. Oncinfo contributes in this study through analysis of gene expression and DNA methylation profiles.

Data

  1. DNA methylation data of 29 subjects were measured in 2019 using Infinium MethylationEpic V1 Array. PBMC samples were collected before and after Rapamycin (16 subjects) and placebo (13 subjects) treatment for 6-8 weeks.

Collaborators

Dr. Ellen Kraig, an immunologist from the University of Texas Health Science Center at San Antonio.

Dr. Dean Kellogg, a physiologist from the University of Texas Health Science Center at San Antonio.

  1. Niu, Pan-Pan, et al. “Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients.” Journal of translational medicine 12.1 (2014): 170.
    Dean Kellogg mentioned that DDAH2 has already been shown to be regulated by methylation. However, Ellen doesn’t know its transcription state in PBMCs.
  2. Grönniger, Elke, et al. “Aging and chronic sun exposure cause distinct epigenetic changes in human skin.” PLoS genetics 6.5 (2010): e1000971.
  3. Pope, Arthur J., Kanchana Karuppiah, and Arturo J. Cardounel. “Role of the PRMT–DDAH–ADMA axis in the regulation of endothelial nitric oxide production.” Pharmacological research 60.6 (2009): 461-465.
  4. Kanjuh, V., et al. “1P-0066 Severity of coronary arterial stenotic changes correlates with increases in plasma insulin and plasminogen activator inhibitor 1 levels in patients with type 2 diabetes.” Atherosclerosis 2.4 (2003): 33-34.